Seres has completed enrollment for Cohort 2 of the Phase 1b clinical trial of SER-155 in Allo #HSCT patients, bringing us closer to potentially revolutionizing the approach to enteric-derived and bloodstream infections post-transplantation. ir.serestherapeutics.com/news-releases/…

Seres is excited to present new preliminary data on investigational #microbiome therapeutic SER-155 from the first cohort (open-label) of our Phase 1b study in hematopoietic stem cell transplant patients at #ASCO24 in Chicago. Join us at the poster session on June 3rd at 9am

Today, we entered into an agreement w/ partner NestleHealthScience to acquire Vowst, a deal that allows us to focus on our pioneering mission of advancing revolutionary microbiome therapeutics for as many patients as possible. ir.serestherapeutics.com/news-releases/…

Our team had a great time at Friday’s #BioBall event, sponsored by Special Olympics Massachusetts. Not only was it fun to get together, but we helped raise money to support our local #SpecialOlympics athletes! Learn more about the cause:  fundraise.specialolympicsma.org/index.cfm?fuse…

Today we're excited to announce that we've signed the VOWST asset purchase agreement with Nestlé. The completion of the transaction, which is subject to Seres’ shareholder approval and other customary conditions, is expected to occur in the next 90 days. Read the full release:

Today we’re pleased to share Cohort 2 data from our Phase 1b study evaluating SER-155 in patients undergoing allo-HSCT. Read the full release: ir.serestherapeutics.com/news-releases/…

Today we reported our Q3 financial results and provided business updates, including planned next steps for SER-155 following encouraging Phase 1b data in allo-HSCT patients. Read more in the full release: ir.serestherapeutics.com/news-releases/…

Our CEO Eric Shaff will be participating in a fireside chat at the upcoming Piper Sandler Annual Healthcare Conference on December 3rd. Read the release: ir.serestherapeutics.com/news-releases/…

Today we're thrilled to announce that our lead live biotherapeutic, SER-155, has received Breakthrough Therapy Designation from the FDA for the reduction of blood stream infections in adults undergoing an allogeneic stem cell transplant. Read more: ir.serestherapeutics.com/news-releases/…

We're excited to be back in San Francisco for #JPM2025! Join Seres Therapeutics on Thursday, January 16th at 7:30 AM PST for a company overview highlighting our plans to advance our pipeline, including SER-155. ir.serestherapeutics.com/news-releases/…

“We’ve got the right technology, the right team, the right science to change lives, and we're in the process of doing so.” Seres Therapeutics CEO Eric Shaff explains how the company is building on its experience developing VOWST, the first-ever FDA-approved oral life biotherapeutic, as it

Tomorrow morning our team will host a conference call and live video webcast to review our Q4 and full-year 2024 financial results, along with key business updates. Check out our press release for dial-in info: ir.serestherapeutics.com/news-releases/…

This morning we reported Q4 and full year 2024 earnings. In addition, we shared updates regarding upcoming milestones for our lead live biotherapeutic, SER-155. Read more in the full release: ir.serestherapeutics.com/news-releases/… View the webcast replay: edge.media-server.com/mmc/p/77xyymqc

Seres will be at #EBMT25 sharing data from our Phase 1b placebo-controlled study of SER-155 in allo-HSCT patients. Poster abstract (A178): ebmt2025.abstractserver.com/program/#/deta… Oral presentation abstract (OS16-01): ebmt2025.abstractserver.com/program/#/deta…

Digestive Disease Week is just around the corner! Our team will be presenting three posters highlighting new results that could help identify candidate biomarkers to support the further clinical development of live biotherapeutics to treat inflammatory and immune diseases,

We’re looking forward to sharing our Q1 2025 financial results and business updates this Wednesday, May 7 at 8:30am EST. Dial-in info can be found in our recent release: ir.serestherapeutics.com/news-releases/…

This morning we shared our Q1 results and business updates. SER-155 is planning for a Phase 2 following FDA feedback, with new exploratory biomarker data supporting its potential in BSIs and broader immune/inflammatory diseases. Strategic partnership discussions for SER-155 are

We’re excited to present new SER-155 Phase 1b exploratory biomarker data at #ASCO25. If you’re attending, we welcome you to stop by our poster and learn more! Read more: ir.serestherapeutics.com/news-releases/…

Mark your calendars—our team will be sharing Q2 earnings and business updates this Wednesday, August 6 at 8:30am EST. Details and conference call information can be found here: ir.serestherapeutics.com/news-releases/…

This morning our team reported Q2 2025 financial results and business updates. We will also be holding a conference call at 8:30am EST, and a webcast will be available approximately two hours following the event. Full release: ir.serestherapeutics.com/news-releases/…